Ginsenoside Rh2 alleviates dextran sulfate sodium-induced colitis via augmenting TGFβ signaling

Molecular Biology Reports

Volumn 41, Issue 8, 2014, Pages 5485-5490

  Ye, Hua ^a   Wu, Qiong ^a   Zhu, Yuzhen ^a   Guo, Cancan ^a   Zheng, Xuebao ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Colitis; Dextran sulfate sodium; Ginsenoside Rh2; SB431542; TGF signaling

Indexed keywords

DEXTRAN SULFATE; GINSENOSIDE RH 2; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; GINSENOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; STOMACH LAVAGE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; METABOLISM;

MUS;

ANIMALS; COLITIS; COLON; DEXTRAN SULFATE; GINSENOSIDES; MALE; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84905114410     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3422-0     Document Type: Article

References (25)

1. Uhlig HH (2013) Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut 62:1795-1805
2. Plevy SE, Targan SR (2011) Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology 140:1838-1846
3. Strober W, Fuss IJ (2011) Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140:1756-1767
4. Rutgeerts P, Vermeire S, Van Assche G (2009) Biological therapies for inflammatory bowel diseases. Gastroenterology 136:1182-1197
5. Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134:577-594
6. Sartor RB (2006) Microbial and dietary factors in the pathogenesis of chronic, immune-mediated intestinal inflammation. Adv Exp Med Biol 579:35-54
7. Strober W, Fuss I, Mannon P (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117:514-521 (Pubitemid 46348505)
8. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694-702 (Pubitemid 20069706)
9. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG et al (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114:385-391 (Pubitemid 28539597)
10. Wang C, Chen J, Sun L, Liu Y (2014) TGF-beta signaling-dependent alleviation of dextran sulfate sodium-induced colitis by mesenchymal stem cell transplantation. Mol Biol Rep. doi:10.1007/s11033-014-3364-6
11. Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T et al (2014) EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2. Tumour Biol. doi:10.1007/s13277-014-1739-x
12. Bi WY, Fu BD, Shen HQ, Wei Q, Zhang C, Song Z et al (2012) Sulfated derivative of 20(S)-ginsenoside Rh2 inhibits inflammatory cytokines through MAPKs and NF-kappa B pathways in LPS-induced RAW264.7 macrophages. Inflammation 35:1659-1668
13. Lee WK, Kao ST, Liu IM, Cheng JT (2007) Ginsenoside Rh2 is one of the active principles of Panax ginseng root to improve insulin sensitivity in fructose-rich chow-fed rats. Horm Metab Res 39:347-354
14. Zhu JH, Takeshita T, Kitagawa I, Morimoto K (1995) Suppression of the formation of sister chromatid exchanges by low concentrations of ginsenoside Rh2 in human blood lymphocytes. Cancer Res 55:1221-1223
15. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP et al (2002) Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 45:999-1001 (Pubitemid 34173910)
16. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C et al (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58-64 (Pubitemid 34680516)
17. Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K et al (2003) SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res 63:7791-7798 (Pubitemid 37466711)
18. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD et al (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65-74 (Pubitemid 34680517)
19. Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L et al (2014) M2 macrophages promote beta-cell proliferation by upregulation of SMAD7. Proc Natl Acad Sci USA 111:E1211-E1220
20. Fish J, Healy J, Gensure R, Choe E, Ferrara J (1993) Effect of peritoneal and gastric irrigation with ozonated saline on arterial and venous blood gas values. Life Sci 53:1867-1872
21. Wirtz S, Neufert C, Weigmann B, Neurath MF (2007) Chemically induced mouse models of intestinal inflammation. Nat Protoc 2:541-546 (Pubitemid 47040018)
22. Maunder RG, Greenberg GR (2004) Comparison of a disease activity index and patients' self-reported symptom severity in ulcerative colitis. Inflamm Bowel Dis 10:632-636 (Pubitemid 39276473)
23. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M (1992) An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 87:971-976
24. Rutegard I, Ahsgren L, Stenling R, Nilsson T (1990) A simple index for assessment of disease activity in patients with ulcerative colitis. Hepatogastroenterology 37(Suppl 2):110-112
25. Campbell CF (2010) Isolation and culture of mouse intestinal cells. Methods Mol Biol 633:197-206